Amneal Pharmaceuticals (AMRX) announced the launch of mesalamine 800 mg delayed-release tablets, an aminosalicylate indicated for the treatment ...

The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

Pfizer (PFE) announced that the U.S. FDA has approved the supplemental Biologics License Application for ADCETRIS in combination with lenalidomide ...

Idecabtagene vicleucel induced high complete response and minimal residual disease negativity rates in multiple myeloma after ...

Approval is based on positive data from the Phase 3 ECHELON-3 trial, which demonstrated ADCETRIS regimen reduced the risk of ...

A five-year study has found that adding daratumumab (D) to the current standard-of-care triplet therapy bortezomib, lenalidomide, and dexamethasone (VRd) produced deeper and more durable minimal ...

NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with $63.6 billion in annual revenue and an impressive 74% gross profit margin, has announced the U.S. Food and Drug Administration's ...

In the phase 3, randomized CARTITUDE-4 trial involving patients with lenalidomide-refractory multiple myeloma who had received one to three previous lines of therapy, cilta-cel significantly ...

“Mesalamine is a difficult to make product with a limited number of suppliers, and this approval highlights the strength of our R&D capabilities. Additionally, the approval of lenalidomide represents ...

Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...

Additionally, the Company has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for lenalidomide capsules in 2.5 mg, 5 mg ...